| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11085043 | JAZZ PHARMS INC | Euglobulin-based method for determining the biological activity of defibrotide |
Jun, 2032
(8 years from now) | |
| US11746348 | JAZZ PHARMS INC | Euglobulin-based method for determining the biological activity of defibrotide |
Jun, 2032
(8 years from now) | |
| US11236328 | JAZZ PHARMS INC | Euglobulin-based method for determining the biological activity of defibrotide |
Jun, 2032
(8 years from now) | |
Defitelio is owned by Jazz Pharms Inc.
Defitelio contains Defibrotide Sodium.
Defitelio has a total of 3 drug patents out of which 0 drug patents have expired.
Defitelio was authorised for market use on 30 March, 2016.
Defitelio is available in solution;intravenous dosage forms.
Defitelio can be used as treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (hsct).
Drug patent challenges can be filed against Defitelio from 30 March, 2020.
The generics of Defitelio are possible to be released after 22 June, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-112) | Mar 30, 2023 |
| Orphan Drug Exclusivity(ODE) | Mar 30, 2023 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2021 |
Drugs and Companies using DEFIBROTIDE SODIUM ingredient
NCE-1 date: 30 March, 2020
Market Authorisation Date: 30 March, 2016
Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic st...
Dosage: SOLUTION;INTRAVENOUS
DEFITELIO family patents
